GeneHealth - Your precision medicine

Cystic Echinococcosis

Disease Details

Family Health Simplified

Buy Membership

Description: Cystic echinococcosis is a parasitic disease caused by the larval stage of the Echinococcus granulosus tapeworm, forming cysts primarily in the liver and lungs.
Type: Cystic echinococcosis is not a genetic disease; it is an infectious disease caused by the parasitic tapeworm Echinococcus granulosus. There is no genetic transmission involved as it is acquired through ingestion of the parasite's eggs, typically from contaminated food, water, or soil, or through direct contact with animal hosts.
Signs And Symptoms: In the human manifestation of the disease, E. granulosus, E. multilocularis, E. oligarthrus and E. vogeli are localized in the liver (in 75% of cases), the lungs (in 5–15% of cases) and other organs in the body such as the spleen, brain, heart, and kidneys (in 10–20% of cases). In people who are infected with E. granulosus and therefore have cystic echinococcosis, the disease develops as a slow-growing mass in the body. These slow-growing masses, often called cysts, are also found in people that are infected with alveolar and polycystic echinococcosis.The cysts found in those with cystic echinococcosis are usually filled with a clear fluid called hydatid fluid, are spherical, and typically consist of one compartment and are usually only found in one area of the body. While the cysts found in those with alveolar and polycystic echinococcosis are similar to those found in those with cystic echinococcosis, the alveolar and polycystic echinococcosis cysts usually have multiple compartments and have infiltrative as opposed to expansive growth.Depending on the location of the cyst in the body, the person could be asymptomatic even though the cysts have grown to be very large, or be symptomatic even if the cysts are absolutely tiny. If the person is symptomatic, the symptoms will depend largely on where the cysts are located. For instance, if the person has cysts in the lungs and is symptomatic, they will have a cough, shortness of breath and/or pain in the chest.On the other hand, if the person has cysts in the liver and is symptomatic, they will experience abdominal pain, abnormal abdominal tenderness, hepatomegaly with an abdominal mass, jaundice, fever and/or anaphylactic reaction. In addition, if the cysts were to rupture while in the body, whether during surgical extraction of the cysts or by trauma to the body, the person would most likely go into anaphylactic shock and have high fever, pruritus (itching), edema (swelling) of the lips and eyelids, dyspnea, stridor and rhinorrhea.Unlike intermediate hosts, definitive hosts are usually not hurt very much by the infection. Sometimes, a lack of certain vitamins and minerals can be caused in the host by the very high demand of the parasite.The incubation period for all species of Echinococcus can be months to years, or even decades. It largely depends on the location of the cyst in the body and how fast the cyst is growing.
Prognosis: Cystic echinococcosis, also known as hydatid disease, typically has a good prognosis if diagnosed early and treated appropriately. Surgical removal of the cysts is often effective, and antiparasitic medications like albendazole or mebendazole can be used adjunctively or when surgery is not feasible. Delayed diagnosis or inadequate treatment can lead to complications like cyst rupture, secondary infection, and severe organ damage, which worsen the prognosis. Regular follow-up is essential to monitor for and manage potential recurrences.
Onset: Cystic echinococcosis, also known as hydatid disease, typically has a slow and insidious onset. It can take years before symptoms appear, as the cysts grow slowly over time. The disease is often asymptomatic in the early stages and may only be detected incidentally through imaging studies. When symptoms do occur, they depend on the size and location of the cysts, commonly causing abdominal pain, discomfort, and in severe cases, organ dysfunction.
Prevalence: Cystic echinococcosis, also known as hydatid disease, is a parasitic infection caused by the larval stage of the Echinococcus granulosus tapeworm. Its prevalence varies widely across different regions. It is most common in areas where livestock farming is prevalent, such as parts of the Mediterranean, the Middle East, Central Asia, and certain regions in South America and Africa. The infection can be found in both humans and animals, with humans typically becoming accidental hosts. Due to its association with pastoral and farming practices, socioeconomic factors, and local customs, the burden of disease is much higher in rural areas.
Epidemiology: Cystic echinococcosis, also known as hydatid disease, is caused by infection with the larval stage of Echinococcus granulosus. This parasitic infection is most prevalent in areas where livestock farming is common and dogs are used for herding or guarding livestock, such as parts of South America, the Mediterranean basin, the Middle East, and Central Asia. The transmission cycle typically involves dogs as the definitive hosts, which harbor the adult tapeworm in their intestines, and herbivorous livestock or humans as intermediate hosts, where the larval cysts develop. Humans become accidental hosts through the ingestion of tapeworm eggs from contaminated food or water, or through direct contact with infected dogs.
Intractability: Cystic echinococcosis, also known as hydatid disease, can be challenging to treat but is not necessarily intractable. The disease is caused by infection with the larval stage of Echinococcus granulosus, a parasitic tapeworm. Treatment options include antiparasitic medications such as albendazole or mebendazole, surgical removal of cysts, and percutaneous aspiration, injection, and reaspiration (PAIR). The choice of treatment depends on the size, location, and condition of the cysts, as well as the patient's overall health. Early diagnosis and appropriate management are crucial for better outcomes.
Disease Severity: ### Disease Severity of Cystic Echinococcosis

Cystic Echinococcosis, also known as Hydatid disease, is caused by the larval stage of the Echinococcus granulosus tapeworm. Its severity can vary greatly, ranging from asymptomatic to severe, depending on the location, size, and number of cysts formed in the host's body.

- **Asymptomatic Stage**: Many individuals may remain asymptomatic for years as the cysts grow slowly.
- **Symptomatic Stage**: Symptoms appear when cysts cause pressure on surrounding organs. Commonly affected organs include the liver and lungs, but cysts can also form in other organs like the brain and bones.
- **Mild to Moderate Severity**: Symptoms can include abdominal pain, nausea, vomiting, and cough.
- **Severe Cases**: Large cysts or cyst rupture can cause life-threatening complications, such as anaphylactic shock, secondary bacterial infections, and organ dysfunction.

Diagnosis and timely medical or surgical intervention are crucial for managing the disease and reducing morbidity and mortality.
Healthcare Professionals: Disease Ontology ID - DOID:1495
Pathophysiology: Cystic echinococcosis, also known as hydatid disease, is caused by the larval stage of the Echinococcus granulosus tapeworm. The pathophysiology begins when the eggs of the parasite, shed in the feces of the definitive host (typically dogs), are ingested by intermediate hosts (commonly sheep, cattle, and humans) through contaminated food, water, or soil.

Upon ingestion, the eggs hatch in the intestine and release oncospheres that penetrate the intestinal wall and enter the bloodstream. These oncospheres travel to various organs, predominantly the liver and lungs, where they develop into hydatid cysts.

The cysts grow slowly and can become quite large, containing fluid and numerous protoscolices, the larval form of the parasite. The pressure exerted by growing cysts on surrounding tissues can cause symptoms, and cyst rupture can lead to severe allergic reactions or secondary echinococcosis.

Hydatid cysts can cause organ dysfunction due to their size and location. The immune response and local tissue reaction to the cyst can result in fibrosis and inflammation around the cyst, further contributing to organ damage.
Carrier Status: Cystic echinococcosis, also known as hydatid disease, is caused by infection with the larval stage of the Echinococcus granulosus tapeworm. Humans can become accidental intermediate hosts by ingesting eggs released in the feces of definitive hosts, primarily dogs. The disease is characterized by the formation of cysts, predominantly in the liver and lungs, but sometimes in other organs. Transmission does not occur person-to-person; thus, there is no carrier status in the context of human-to-human transmission.
Mechanism: Cystic echinococcosis, also known as hydatid disease, is caused by the larval stage of the parasitic tapeworm Echinococcus granulosus.

**Mechanism:**
1. **Transmission**: The disease is typically transmitted through ingestion of E. granulosus eggs shed in the feces of definitive hosts, commonly dogs or other canids, which have consumed infected intermediate hosts such as sheep.
2. **Lifecycle**: Once ingested, the eggs hatch in the intestines, releasing oncospheres (larval forms) that penetrate the intestinal wall and enter the bloodstream.
3. **Cyst Formation**: The oncospheres migrate to various organs, predominantly the liver and lungs, where they develop into hydatid cysts. These cysts grow slowly, producing protoscolices and daughter cysts, maintaining the parasitic lifecycle.

**Molecular Mechanisms:**
1. **Immune Modulation**: Echinococcus granulosus modulates the host immune response to evade detection. The parasite produces molecules, such as antigen B, that inhibit host immune cell activity and prevent effective immune clearance.
2. **Cyst Formation**: The laminated layer of the cyst wall is rich in glycans and other molecules that help protect the parasite from immune attack. The cyst can secrete various chemical signals that suppress local immune responses.
3. **Growth Factors**: The parasite cyst secretes growth factors that can influence its surrounding environment, promoting tissue remodeling and providing a conducive environment for cyst expansion.
4. **Host-Parasite Interaction**: Molecular studies have identified specific host and parasite proteins involved in adherence, invasion, and modulation of the host environment, contributing to the parasite's survival and pathogenicity.

These mechanisms collectively enable Echinococcus granulosus to establish long-term infections, often going undetected for years within the host.
Treatment: Treatment for cystic echinococcosis typically includes:

1. **Surgery**: Removal of the cyst(s) if they are accessible and surgery is safe.
2. **Antiparasitic Medication**: Albendazole or mebendazole are commonly used to treat the infection.
3. **Percutaneous Aspiration**: A minimally invasive procedure to drain the cyst contents, often followed by scolicidal agents to kill the parasite.
4. **Watch and Wait**: In certain cases, monitoring the cyst over time without immediate intervention may be an option.

Each treatment option depends on the size, location, and condition of the cyst, as well as the overall health of the patient.
Compassionate Use Treatment: For cystic echinococcosis, compassionate use, off-label, and experimental treatments can include:

1. **Albendazole and Mebendazole:** While these anti-parasitic drugs are standard treatments, they may be used under compassionate use or in off-label capacities when other treatments have failed or in specific cases where surgery is not an option.

2. **PAIR Technique:** This involves puncture, aspiration, injection, and reaspiration, and although it is a recognized treatment, it can sometimes be used in an off-label or experimental manner in cases not strictly suited for standard application.

3. **Liposomal Amphotericin B:** This antifungal agent has been explored in experimental settings for its potential effectiveness against echinococcosis, particularly in patients who cannot tolerate conventional antiparasitic drugs.

4. **Nitazoxanide:** This broad-spectrum antiparasitic agent has shown some promise in experimental studies for treating echinococcosis, although it is not yet a standard treatment.

All these treatments underscore a need for close medical supervision given their experimental or off-label status.
Lifestyle Recommendations: For cystic echinococcosis:

**Lifestyle Recommendations:**
1. **Avoid Contact with Infected Animals**: Minimize exposure to livestock and dogs that may carry the parasite.
2. **Practice Good Hygiene**: Wash hands thoroughly with soap and water after handling animals or soil.
3. **Safe Food and Water Consumption**: Avoid consuming unwashed vegetables and drinking untreated water from potentially contaminated sources.
4. **Proper Meat Preparation**: Ensure meat from livestock is cooked thoroughly to kill any present parasites.
5. **Control Animal Hosts**: Regularly deworm pets and manage livestock to reduce the risk of transmission.
6. **Public Health Measures**: Support and participate in community efforts aimed at controlling the spread of the disease through public education and veterinary healthcare initiatives.
Medication: Cystic echinococcosis, also known as hydatid disease, is often treated with a combination of surgery and medication. The primary medications used are antiparasitic agents, typically albendazole or mebendazole. These drugs help reduce the size of the cysts and decrease the risk of complications, although definitive treatment often requires surgical intervention to remove the cysts. Dosage and duration of treatment depend on the size, location, and number of cysts, as well as the patient's overall condition. Consulting with a healthcare professional for an individualized treatment plan is essential.
Repurposable Drugs: For cystic echinococcosis, also known as hydatid disease, some repurposable drugs include albendazole and mebendazole. These are anti-parasitic medications traditionally used to treat infections caused by parasitic worms. Although not always formally repurposed, these drugs are essential in managing this disease.
Metabolites: Cystic echinococcosis, also known as hydatid disease, is caused by the larval stage of the Echinococcus granulosus tapeworm. The disease primarily affects the liver and lungs, forming cysts. Specific metabolites related to this condition include a range of organic acids, amino acids, and sugars that may be altered due to the parasite's metabolic activities.

For example, researchers have identified altered levels of metabolites such as succinic acid, malic acid, and fumaric acid, which are involved in the tricarboxylic acid (TCA) cycle. Additionally, there are changes in lactate, pyruvate, and various amino acids like alanine and proline. These metabolic changes can be potential biomarkers for the diagnosis and monitoring of cystic echinococcosis.
Nutraceuticals: Currently, there is no established evidence to support the efficacy of nutraceuticals in the prevention or treatment of cystic echinococcosis. Medical treatment primarily involves antiparasitic medications like albendazole or mebendazole, and in some cases, surgical intervention may be needed. It is crucial to follow the guidance of healthcare professionals for managing this parasitic infection.
Peptides: For cystic echinococcosis caused by the Echinococcus granulosus tapeworm, peptides and nanoparticles (nan) have been areas of research interest. Specifically, investigators have explored the use of peptide-based diagnostics and treatments to target parasite antigens and nanoparticle delivery systems to enhance the efficacy of drugs such as albendazole. These innovative approaches aim to improve detection, reduce drug resistance, and enhance therapeutic effectiveness.